Shares of Glaukos Corp (NYSE: GKOS), a medical technology company focused on glaucoma treatment, were down about 9.8% as of 11:46 a.m. on Thursday in response to a second-quarter earnings report issued after the bell on Wednesday. Although sales of the company’s pressure-relieving stents are surging, the market isn’t pleased with the bottom line dipping into negative territory.